Skip to contentL
Lifecore Biomedical, Inc.
L
LFCRLifecore Biomedical, Inc. Q4 2020 · 10-K
Revenue$156.13M$156.13M+2.2% vs Q4 2019 Net Income-$15.15M-$15.15MN/M vs Q4 2019 EPS Diluted-$0.52-$0.52N/M vs Q4 2019 Gross Profit$24,091,000−8.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lifecore Biomedical, Inc. · CIK 1005286 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived-$12,703,000N/M Free Cash Flowderived-$2,799,000N/M Margins · derivedGross margin15.4%−1.7 pt vs Q4 2019
Operating margin-0.3%−1.9 pt vs Q4 2019
Net margin-9.7%−9.5 pt vs Q4 2019
ended May 31, 2020 · filed Aug 14, 2020 · 75 d after period end